Drs. Meredith McKean, Dr. Doug Micalizzi and patient advocate and lung cancer survivor, Ivy Elkins, discuss the importance of early detection and treatment across cancer types, including skin, lung, and breast. To watch the complete playlist click here .
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 107
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Please Note: New Treatments Have Emerged Since this Original Post
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic
Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.